Western University (Tenomix)

tenomix.com
Innovation Type:
Diagnostics
Cancer Type:
Other
Funding Stage:
Proof of Concept
Fund:
Prospects
A bench-top ultrasound-based device that can automate the detection of lymph nodes in resected colorectal cancer tissue

Related news

FACIT broadens Executive-in-Residence program to capitalize on Ontario IP

The appointment broadens the available expertise to provide critical senior management and leadership to create and nurture FACIT start-ups in Ontario. Read More

Fluorinov Pharma Inc. develops drug for the treatment of blood cancers

OICR will provide $1.5 million for the development of FV-162, a highly potent, orally-delivered small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin’s lymphoma. Read More

Xagenic Inc. Raises $10 Million to Advance Commercialization of Breakthrough Screening Technology

Investors in the Series A round included CTI Life Sciences Fund L.P., Qiagen N.V. and Ontario Capital Growth Corporation through its Emerging Technologies Fund. Read More

OICR and MaRS Innovation announce funding for the development of Cellax™

Cellax™, invented by OICR researchers, is a drug-polymer conjugate based on the proprietary NanoCMC™ technology. Read More

Triphase Signs Collaboration and Option Agreement with Celgene Corporation

Triphase was spun out of the Ontario Institute for Cancer Research to develop and advance late pre-clinical, Phase I or early Phase II potential products. Read More

Fluorinov, FACIT and OICR announce novel candidate drugs

The candidate drugs have shown excellent preliminary safety profiles, improved treatment and expect to have fewer sedative side effects. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.